A59 SEVERE CHEMOTHERAPY-INDUCED SECRETORY DIARRHEA
نویسندگان
چکیده
منابع مشابه
Octreotide in the treatment of severe chemotherapy-induced diarrhea.
BACKGROUND Chemotherapy-induced diarrhea (CID) is a common side effect of a number of chemotherapeutic agents. Conventional therapy for severe CID with opioids or loperamide is moderately effective. A prospective trial was conducted using octreotide acetate for treatment of severe CID refractory to loperamide. PATIENTS AND METHODS Thirty-two patients with grade 2 and 3 CID refractory to loper...
متن کاملOverview of chemotherapy-induced diarrhea.
OBJECTIVES To provide a general overview of chemotherapy-induced diarrhea (CID) that will highlight the pathophysiology, incidence, and impact of this problem, as well as describe the oncology nurse's role in the management of CID. DATA SOURCES Primary and tertiary literature, the authors' clinical experience. CONCLUSION CID is a frequent complication of many types of chemotherapy that can ...
متن کاملManagement of Secretory Diarrhea
“Diarrhea is the passage of 3 or more loose or liquid stool per day, or more frequently than is normal for the individual. It is usually a symptom of gastrointestinal infection, which can be caused by a variety of bacterial, viral and parasitic organisms, infection is spread through contaminated food or drinking-water, or from person to person as a result of poor hygiene” (WHO). Diarrheal disea...
متن کاملChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments
Gastrointestinal (GI) side-effects of chemotherapy are a debilitating and often overlooked clinical hurdle in cancer management. Chemotherapy-induced constipation (CIC) and Diarrhea (CID) present a constant challenge in the efficient and tolerable treatment of cancer and are amongst the primary contributors to dose reductions, delays and cessation of treatment. Although prevalence of CIC is har...
متن کاملTrastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
Sir, Taxanes, which are inhibitors of tubulin function in mitosis and used as cancer chemotherapy, are well known to be associated with onychopathy. Trastuzumab, a recombinant DNA‐derived humanized monoclonal antibody against the human epidermal growth factor receptor 2 protein (HER‐2) is used in combination with taxanes in advanced stage HER‐2 positive metastatic breast cancer.[1] We report th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Canadian Association of Gastroenterology
سال: 2021
ISSN: 2515-2084,2515-2092
DOI: 10.1093/jcag/gwab002.057